Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drug Safety
Published in: Drug Safety 10/2006

01-10-2006 | Abstracts

ABSTRACTS: ISoP Annual Conference ‘Joining Forces for Managing Risks’ Liège, Belgium 11–13 October, 2006

Authors: S. Schmiedl, J. Szymanski, M. Rottenkolber, B. Drewelow, G. Haase, M. Hippius, I. R. Reimann, W. Siegmund, K. May, J. Hasford, P. A. Thuermann

Published in: Drug Safety | Issue 10/2006

Login to get access

Excerpt

Background: Approximately 258 Mio DDDs of digitalis glycosides (DGs) are prescribed annually in Germany, mainly digitoxin, followed by β-acetyldigoxin.[1] DGs are well-known for their narrow therapeutic range. Their value in the treatment of heart failure is limited and sex differences in terms of outcome have been reported, where women seem to benefit less than men.[2] …
Literature
1.
Schröder H, Selke W. Arzneimittelverordnungen nach Alter und Geschlecht. In: Schwabe U, Paffrath D (Hrsg): Arzneiverordnungs-Report 2003. Berlin: Springer Verlag, 959–71
2.
Adams KF, Patterson JH, Gattis WA, et al. Relationship of serum digoxin concentration to mortality and morbidity in women in the Digitalis Investigation Group Trial. A retrospective analysis. J Am Coll Cardiol 2005; 46: 497–504PubMedCrossRef
3.
Schneeweiss S, Hasford J, Göttler M, et al. Admissions caused by adverse drug events to internal medicine and emergency departments in hospitals: a longitudinal population-based study. Eur J Clin Pharmacol 2002; 58: 285–91PubMedCrossRef
4.
German Summary of Product Characteristics: Fachinformation Digimerck®, Merck KG, Status Januar 2001
5.
Bruns A, Reil G-H. Herzinsuffizienz. In: Alexander K, Daniel WG, Diener HG. C, et al. (Hrsg.):Thiemes Innere Medizin 1999; 1070–88
Metadata
Title
ABSTRACTS: ISoP Annual Conference ‘Joining Forces for Managing Risks’ Liège, Belgium 11–13 October, 2006
Authors
S. Schmiedl
J. Szymanski
M. Rottenkolber
B. Drewelow
G. Haase
M. Hippius
I. R. Reimann
W. Siegmund
K. May
J. Hasford
P. A. Thuermann
Publication date
01-10-2006
Publisher
Springer International Publishing
Published in
Drug Safety / Issue 10/2006
Print ISSN: 0114-5916
Electronic ISSN: 1179-1942
DOI
https://doi.org/10.2165/00002018-200629100-00070

Other articles of this Issue 10/2006

Drug Safety 10/2006 Go to the issue

Abstracts

ABSTRACTS: ISoP Annual Conference ‘Joining Forces for Managing Risks’ Liège, Belgium 11–13 October, 2006

Abstracts

ABSTRACTS: ISoP Annual Conference ‘Joining Forces for Managing Risks’ Liège, Belgium 11–13 October, 2006

Abstracts

ABSTRACTS: ISoP Annual Conference ‘Joining Forces for Managing Risks’ Liège, Belgium 11–13 October, 2006

Abstracts

ABSTRACTS: ISoP Annual Conference ‘Joining Forces for Managing Risks’ Liège, Belgium 11–13 October, 2006

Abstracts

ABSTRACTS: ISoP Annual Conference ‘Joining Forces for Managing Risks’ Liège, Belgium 11–13 October, 2006

Abstracts

ABSTRACTS: ISoP Annual Conference ‘Joining Forces for Managing Risks’ Liège, Belgium 11–13 October, 2006